ViaCyte Selects Michael Yang as New President and CEO

Regenerative medicine developer ViaCyte has appointed Michael Yang to lead the company as its new president and CEO.

Yang brings more than 20 years of commercialization and top-level leadership experience in medical device, biotech and pharmaceutical companies to leading ViaCyte. He last served as Acadia Pharmaceuticals’ executive vice president and chief commercial officer.

The San Diego, Calif., company focuses on developing novel cell replacement therapies based on cell encapsulation and implantation devices, and cell replacement therapies derived from pluripotent stem cells.